Antibe Therapeutics Inc(Pre-Merger) ATBPF

Good News

[crow27]

When it comes we run by dollars not pennies. Hopefully you were all buying in that $3.50 range. This is still dirt cheap when you consider where it will be going?
$20, $30, $40 are what we should be looking at. $3.97 is very, very cheap for what this has to offer.
Anyway, load up and Happy New Year to all the longs.

[Marky1]

Well said sir Crowe...Totally agree! We should be at s Market Cap of at least 600 M USD $$. that puts the SP at 20$...and that's very very cheap..IMHO

[Doccole]

With biopharm and deals- say we make a licensing partnership deal with LATAM and it ups our cash position to 350m at 10%.  What would our stock most likely trade at? I imagine it would be much higher than a market cap of 350m. i was looking online for examples, but I didn't know the way biopharm stocks are evaluated once a deal/cash infusion is established.  Dan said right now we

[MrMugsy]

Tough to say how it plays out. There are good negotiations and there are bad negotiations. Hoping ATE can make partners see it their way - then shareholders will drive the price up on the buying spree.  IMO.

[Doccole]

Gotcha, I guess it's how the market interprets the company and deal.  Fingers crossed.   I've been doing some research and this may pop to 15 on a Nasdq uplist on its own.  

[RalphRalph]

If you're talking about an upfront payment on a licensing deal, I don't think there's much chance they get anything close to $300 million upfront payment.  I'd expect something closer to $30 - $40 million. Given the volume of sales 346 could do, I'd rather they push for a larger royalty rate if they have to prioritize one of the two.  I would hope ideally for a

[Doccole]

The number I put out there were just number.  Trying to gain a perspective. Thanks for your insights.

[MrMugsy]

True - but I have a number between the two of your numbers if the right components are added to a deal.  It could be rights for one drug or the family of drugs ... there could be an investment stake for cash buried in the agreement.  Heck ... there could be a loan component with assets as collateral (less likelyt to be used).  There could be right-of-first-refusal on future drugs

[Marky1]

You know, if you look back at the history of ATB 346, but I have never seen anything negative being shown about this drug...Someone lied about his past medical history caused the stock to plummet down to almost zero back in 2014 I have seen any negative effects from 346....The low P values are a fact..statistics don't lie..they were developed to be an honest judge of a test...no impartially

[bringon10bagger]

No dreaming here  Marky......With 346 crossing the fiish line 1st, and with a broaden view of what;s to come, 352 and 340 how does one place a value on the full meal deal and adding other variations....ATB-???....a  true valuation is in the billions 5, 10, 20, 30 and beyond.......lets see how hungry big pharma's are .....imho....STARVING.....All the best to the longs in 2021.......

[themagicbox]

Not to mention the new research coming out of the "university-that-cannot-be-named" discussed in the latest biopub. That will create both new IP and new patents that go far beyond the data protection and organge book patents for Oten/346. The wild card will be what comes from the research on covid and if the different pipeline drugs have a therapeutic effect on COVID 

[MrMugsy]

I find COVID to be an interesting topic based on a few facts ... 1.  They can't discuss details (other than an NDA, what other reason?).  Could there be a partnership on this side. 2.  Antibe is looking to get deeper into gaseous mediators and this alone spells exciting new approaches to dealing with inflamation, the root cause in some respects. 3.  Think viruses and think

[MrMugsy]

Oh ... as the article leads into ... even repairing damage to lungs.  That gets us back full circle to OTENA and the reduction in ulceration.  Next step after that ... repairing stomach ulcers.  None of this is beyond ATE's abilities and ... I would bet ... Wallace has already travelled quite a distance down this road, with his iron sucking drugs to reduce pain associated with

[themagicbox]

I think thats the avenue they're taking with the new IP research. How h2s delivered through an NSAID can potentially affect other systems with a therapuetic benefit(s). This will take a while, as it has to go through same phases as otena but makes for an attractive package for a potential buyout.  At the end of the day, ATE as a company, their compentency is a drug development. Not